当前位置: 首页 行业新闻 智能泵:胰岛素内

行业新闻

原文:
New microchip technology has led to the creation of an advanced, implantable insulin pump that may eventually free diabetics from troublesome daily insulin injections. Engineers at the University of Delaware have developed algorithms small enough to fit on a chip that can monitor and control blood-sugar levels. The chip could be embedded in a surgically implanted insulinSafety Relief Valves pump that could release insulin as needed and be refilled monthly, researchers said. Read ongoing Med-Tech coverage "The key thing is to make a diabetic person feel as close to a healthy and normal person as possible," said Francis J. Doyle III, an associate professor of chemical engineering at the college and a co-developer of the technology. "That means a lifestyle without multiple injections with a needle and a lifestyle without a pump hanging from their hip," he said. "The device would act as an artificial pancreas, much like a pacemaker." The details of the research were announced Monday at a conference of the Association for the Advancement of Medical Instrumentation in Boston. The system closely controls blood sugar levels in Type I or insulin-dependent diabetics by continuously predicting the patient's need for insulin. "We want to take the patient out of the loop and make it so they don't have to think about anything," said Robert S. Parker, doctoral candidate and co-developer of the research. The algorithm would analyze glucose readings from a sensor and instruct the mechanical pump to deliver the appropriate dose of insulin to the patient, Parker said. Normally, diabetics must take their own glucose measurements and correct their blood sugar levels with a self-administered insulin injection, Parker Balance Valves said. The device would likely be placed near the left hip, close to the portal vein, which is the blood vessel between the stomach and the liver where the pancreas normally releases insulin into the bloodstream. The surgery to implant the pump would be a complex procedure, Parker said, but beyond that, the device would be designed for easy maintenance. Refills of the pump's insulin reservoir would probably require a monthly, outpatient injection. "It's an injection once a month into the pump, down from three or four a day," Parker said. While news of the chip is encouraging to many of the nation's 16 million diabetics, doctors caution that an artificial pancreas will not be available anytime soon. The project, which is sponsored by Roche Diagnostics and by the National Science Foundation is at least three years from reaching the market. Still, recent advances look promising. An implantable pump by MiniMed Technologies is currently being tested and there are several other companies at work on sensor technology. "If this algorithm proves to be as good as they say, it may be an important link between the sensor and the pump," said Dr. Michael Bush, former presidentNeedle & Gauge Valves of the American Diabetes Association. "But [people] need to realize it'll still take a number of years to prove whether this can be used effectively."
原文来自: http://www.wired.com/science/discoveries/news/1999/06/20075

The Smart Pump: Insulin Inside;是由 上海赛泰泵阀有限公司提供的阀门新闻,中文译文仅供参考(上海赛泰泵阀有限公司还生产 针型阀 调节阀 锻钢阀门 疏水阀 电磁阀 及气动薄膜隔膜调节阀,JJY1卡套式针型阀,偏心旋转调节阀,自力式差压调节阀,电动衬氟调节蝶阀,欢迎您的选购。)
以下是参考译文:

译文:
新的芯片技术已导致先进,胰岛素泵植入可能最终摆脱麻烦,每天注射胰岛素糖尿病患者的创建。 在特拉华大学的工程师们开发的算法小到可以在一个芯片上,可以监视和控制血糖水平。 该芯片可在手术植入胰岛素泵可释放胰岛素,需要重新获得每月嵌入,研究人员说。 正在读医学科技报道 “关键是要作出糖尿病人感到接近尽可能健康正常的人,”多伊尔说,弗朗西斯是化学工程学院,并在共同副教授第三,这项技术的开发商。 “这意味着一个没有用一根针和生活方式多次注射没有从他们的臀部挂泵的生活方式,”他说。 “该设备可以作为一个人工胰脏,就像心脏起搏器。” 这项研究的细节日宣布在该协会发布的医疗器械促进会议在波士顿。 该系统的控制,不断密切预测患者对胰岛素的需要I类或胰岛素依赖型糖尿病患者的血糖水平。 “我们希望把病人进行循环,使它这样他们就不用考虑什么,说:”罗伯特,博士生和合作帕克的研究开发。 该算法将分析从一个传感器血糖,并指示机械泵提供了适当剂量胰岛素的病人,帕克说。 一般来说,糖尿病患者必须采取自己的血糖测量和纠正他们的血液与血糖水平的自我管理的胰岛素注射,帕克说。 该设备可能会被放置在左臀部附近,靠近门静脉,这是与胃和肝血管在正常的胰腺释放到血液中的胰岛素。 该手术植入泵将是一个复杂的过程,帕克说,但除此之外,该装置将设计,便于维修。 该泵的胰岛素水库笔芯就可能需要每月门诊注射。 “这是一次注射泵入二个月下跌,从三四天,”帕克说。 虽然该芯片的消息令人鼓舞的是全国1600万糖尿病患者多,医生警告说,人工胰腺将无法很快。 该项目是由罗氏诊断和美国国家科学基金会是由至少3年流入市面。 不过,最近的发展看好。一个由MiniMed泵植入技术,目前正在测试,也有其他的传感器技术工作的若干其他公司。 “如果这种算法被证明是一样好,他们说,这可能是一种与传感器和泵的重要环节,博士说:”迈克尔布什,美国糖尿病协会的前主席。 “但是,[人]需要认识到它仍然需要数年,以证明是否可以有效地加以利用。”